| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $14,268,144 | 55 | 100 |
| Vairavan Latha | SVP Chief Financial Officer | 0 | $0 | 5 | $148,496 | $-148,496 |
| Gilbert Halley E | director | 0 | $0 | 1 | $455,442 | $-455,442 |
| Curran Terrie | director | 0 | $0 | 2 | $705,008 | $-705,008 |
| Edwards Larry Todd | See Remarks | 0 | $0 | 3 | $878,096 | $-878,096 |
| LIN SUE-JEAN | director | 0 | $0 | 2 | $898,543 | $-898,543 |
| Krishnamohan Neha | director | 0 | $0 | 1 | $939,494 | $-939,494 |
| Leonard Keith R | director | 0 | $0 | 1 | $997,195 | $-997,195 |
| Burnett Patrick | See Remarks | 0 | $0 | 15 | $2.02M | $-2.02M |
| Matsuda Masaru | See Remarks | 0 | $0 | 10 | $2.21M | $-2.21M |
| Welgus Howard G. | director | 0 | $0 | 13 | $2.36M | $-2.36M |
| Watanabe Todd | See Remarks | 0 | $0 | 7 | $3.44M | $-3.44M |
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and …
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $0 and sold $14.27M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $1.46M and sold $6.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,646 shares for transaction amount of $34,610 was made by Heron Patrick J (director) on 2025‑06‑13.
| 2026-10-15 | Sale | Welgus Howard G. | director | 4,728 0.0035% | $26.93 | $127,325 | +9.52% | |
| 2026-09-16 | Sale | Matsuda Masaru | See Remarks | 3,674 0.0028% | $25.00 | $91,853 | +2.66% | |
| 2026-09-15 | Sale | Welgus Howard G. | director | 4,730 0.0039% | $24.18 | $114,371 | +13.78% | |
| 2026-09-08 | Sale | Matsuda Masaru | See Remarks | 9,989 0.0079% | $25.03 | $249,986 | +8.43% | |
| 2026-08-27 | Sale | Curran Terrie | director | 27,052 0.0218% | $25.03 | $677,095 | +5.63% | |
| 2026-08-20 | Sale | Curran Terrie | director | 1,072 0.0008% | $26.04 | $27,912 | +3.02% | |
| 2026-08-19 | Sale | Burnett Patrick | See Remarks | 1,697 0.0014% | $27.00 | $45,819 | -1.40% | |
| 2026-08-17 | Sale | Welgus Howard G. | director | 4,730 0.0037% | $26.18 | $123,835 | +2.07% | |
| 2026-08-12 | Sale | Burnett Patrick | See Remarks | 6,700 0.0053% | $26.08 | $174,767 | -0.63% | |
| 2026-08-11 | Sale | Burnett Patrick | See Remarks | 8,300 0.0067% | $26.52 | $220,129 | -0.34% | |
| 2026-08-03 | Sale | Watanabe Todd | See Remarks | 4,375 0.0034% | $26.12 | $114,261 | +0.77% | |
| 2026-08-03 | Sale | Matsuda Masaru | See Remarks | 1,230 0.001% | $26.12 | $32,124 | +0.77% | |
| 2026-08-03 | Sale | Burnett Patrick | See Remarks | 955 0.0007% | $26.12 | $24,942 | +0.77% | |
| 2026-07-15 | Sale | Welgus Howard G. | director | 4,730 0.0037% | $26.91 | $127,284 | -5.22% | |
| 2026-06-17 | Sale | Welgus Howard G. | director | 635 0.0005% | $25.67 | $16,300 | +0.80% | |
| 2026-06-15 | Sale | Welgus Howard G. | director | 4,096 0.0031% | $24.41 | $99,980 | +3.28% | |
| 2026-06-15 | Sale | LIN SUE-JEAN | director | 4,946 0.0038% | $24.38 | $120,587 | +3.28% | |
| 2026-05-11 | Sale | Burnett Patrick | See Remarks | 222 0.0002% | $21.05 | $4,673 | +22.95% | |
| 2026-05-11 | Sale | Vairavan Latha | SVP Chief Financial Officer | 435 0.0003% | $21.05 | $9,157 | +22.95% | |
| 2026-05-04 | Sale | Watanabe Todd | See Remarks | 3,172 0.0025% | $23.61 | $74,893 | +10.81% |
| Watanabe Todd | See Remarks | 717203 0.5706% | $22.95M | 3 | 64 | +14.82% |
| Edwards Larry Todd | See Remarks | 175178 0.1394% | $5.61M | 1 | 8 | 0% |
| Matsuda Masaru | See Remarks | 112508 0.0895% | $3.6M | 2 | 27 | +18.84% |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 6.9728% | $280.46M | 2 | 0 | +140.17% |
| ORBIMED ADVISORS LLC | 4267564 3.3953% | $136.56M | 2 | 0 | +10.62% | |
| SILVERSTEIN JONATHAN | 4267564 3.3953% | $136.56M | 2 | 0 | +10.62% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 3979292 3.1659% | $127.34M | 1 | 0 | +5.03% |
| Heron Patrick J | director | 27448 0.0218% | $878,336.00 | 12 | 0 | +44.95% |
$224,662,742 | 52 | 32.03% | $5.65B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B |
| Increased Positions | 178 | +75.42% | 21M | +16.42% |
| Decreased Positions | 102 | -43.22% | 17M | -13.45% |
| New Positions | 74 | New | 7M | New |
| Sold Out Positions | 26 | Sold Out | 3M | Sold Out |
| Total Postitions | 312 | +32.2% | 130M | +2.97% |
| Jennison Associates Llc | $355,369.00 | 10.04% | 12.25M | +1M | +10.3% | 2025-09-30 |
| Rubric Capital Management Lp | $311,734.00 | 8.81% | 10.75M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $303,862.00 | 8.59% | 10.48M | -1M | -9.17% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $286,361.00 | 8.09% | 9.87M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $248,646.00 | 7.03% | 8.57M | +41,234 | +0.48% | 2025-09-30 |
| Vanguard Group Inc | $207,237.00 | 5.86% | 7.15M | +96,991 | +1.38% | 2025-09-30 |
| Polar Capital Holdings Plc | $153,664.00 | 4.34% | 5.3M | +292,279 | +5.84% | 2025-09-30 |
| State Street Corp | $134,598.00 | 3.8% | 4.64M | +114,378 | +2.53% | 2025-09-30 |
| Gilder Gagnon Howe & Co Llc | $128,444.00 | 3.63% | 4.43M | +273,345 | +6.58% | 2025-09-30 |
| Morgan Stanley | $124,015.00 | 3.51% | 4.28M | -38,136 | -0.88% | 2025-09-30 |